{"product_id":"myo-vrio-analysis","title":"Myomo, Inc. (MYO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Myomo, Inc. (MYO) truly built to last? Our VRIO analysis cuts straight to the core of its competitive edge, revealing that its current strengths are summarized by: \u0026amp;O4\u0026amp;. Dive in now to see exactly which resources give this business its staying power - or where the vulnerabilities lie.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: MyoPro Wearable Robotics Platform (Intellectual Property)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset of Myomo, Inc. (MYO), the MyoPro system, and trying to figure out if that intellectual property (IP) can actually deliver a lasting competitive edge. Honestly, the tech itself is impressive, but the financial execution tells a more nuanced story about its current advantage.\u003c\/p\u003e\n\n\u003ch\u003eValue: Enables Precise Functionality\u003c\/h\u003e\n\u003cp\u003eThe MyoPro platform creates functional movement for patients with upper-limb paralysis by reading myoelectric signals. This capability directly supports its premium pricing structure. For instance, the Average Selling Price (ASP) in the third quarter of 2025 settled at approximately \u003cstrong\u003e$54,200\u003c\/strong\u003e per unit. That price point is only sustainable because the device delivers a tangible, life-improving outcome that alternatives struggle to match.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Specialized Regulatory Status\u003c\/h\u003e\n\u003cp\u003eWhat makes the MyoPro rare right now isn't just the engineering; it's the regulatory pathway. The MyoPro 2x device is a Listed FDA Class-2 product that is 510-K exempt. This specific clearance status for this class of assistive robotics isn't something you see every day from competitors trying to enter the market quickly. It means the barrier to entry isn't just R\u0026amp;D spend; it’s navigating a specific, established regulatory channel.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High Hurdles for Fast-Followers\u003c\/h\u003e\n\u003cp\u003eImitating this technology is tough, which is good for Myomo. The difficulty lies in the deep integration of the custom hardware, the proprietary software interpreting the weak muscle signals, and the established regulatory framework. Building a similar system from scratch would require significant time and capital to replicate the proven performance and clearance history. It’s not just copying schematics; it’s replicating years of clinical validation.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Operational Leverage Needed\u003c\/h\u003e\n\u003cp\u003eHere’s where the picture gets a bit fuzzy. While the product is strong, the company’s organization isn't fully capitalizing on it yet. The gross margin for Q3 2025 was \u003cstrong\u003e63.8%\u003c\/strong\u003e, a notable drop from 75.4% in the prior year quarter, driven by higher material and overhead costs tied to the new headquarters. Revenue for the quarter was \u003cstrong\u003e$10.1 million\u003c\/strong\u003e, but the operating loss was \u003cstrong\u003e$3.5 million\u003c\/strong\u003e. You defintely need to see those margins improve to fully leverage this IP.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary Status Quo\u003c\/h\u003e\n\u003cp\u003eBased on the current assessment, the competitive advantage is best described as temporary. The IP provides a current moat due to its rarity and difficulty to copy, but this advantage erodes if Myomo, Inc. doesn't convert its revenue growth into superior profitability. Sustaining this edge means continuously outspending and out-innovating any potential fast-followers before they clear their own regulatory hurdles.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how these dimensions stack up against the required resources:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eSupporting Metric\/Observation\u003c\/th\u003e\n\u003cth\u003eScore Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eASP of \u003cstrong\u003e$54,200\u003c\/strong\u003e in Q3 2025\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eFDA Class-2, 510-K exempt status\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh hardware\/software integration \u0026amp; regulatory barriers\u003c\/td\u003e\n\u003ctd\u003eDifficult to Imitate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eGross Margin of \u003cstrong\u003e63.8%\u003c\/strong\u003e (Q3 2025); Operating Loss of \u003cstrong\u003e$3.5M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNot Fully Organized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTechnology protected, but operational efficiency lags\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe immediate focus needs to be on operationalizing the sales better. The company recognized revenue on 186 MyoPro units in Q3 2025, a 16% increase year-over-year, but the margin compression is a red flag. We need to see the MyoConnect program translate into better unit economics.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImprove gross margin above 70% target.\u003c\/li\u003e\n\u003cli\u003eReduce cost per pipeline add (was $2,589 in Q3 2025).\u003c\/li\u003e\n\u003cli\u003eIncrease cash runway beyond 12 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: Medicare Part B Reimbursement Status\n\u003c\/h2\u003e\n\u003cp\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eProvides access to the core U.S. patient base; Medicare Part B patients drove \u003cstrong\u003e59%\u003c\/strong\u003e of Q1 2025 revenue.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e$3.8 million\u003c\/td\u003e\n\u003ctd\u003e$12.1 million\u003c\/td\u003e\n\u003ctd\u003e$9.8 million\u003c\/td\u003e\n\u003ctd\u003e$10.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part B Revenue Share\u003c\/td\u003e\n\u003ctd\u003eVery few\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Units\u003c\/td\u003e\n\u003ctd\u003e91\u003c\/td\u003e\n\u003ctd\u003e220\u003c\/td\u003e\n\u003ctd\u003e182\u003c\/td\u003e\n\u003ctd\u003e186\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eQ1 2025 Revenue recognized on \u003cstrong\u003e182\u003c\/strong\u003e MyoPro units, up \u003cstrong\u003e100%\u003c\/strong\u003e over Q1 2024.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Average Selling Price (ASP) was approximately \u003cstrong\u003e$54,000\u003c\/strong\u003e, up \u003cstrong\u003e31%\u003c\/strong\u003e over Q1 2024.\u003c\/li\u003e\n\u003cli\u003eCMS fees for the MyoPro became effective in April 2024.\u003c\/li\u003e\n\u003cli\u003eBacklog included \u003cstrong\u003e83\u003c\/strong\u003e Medicare Part B patients as of March 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. While other devices get coverage, securing and maintaining favorable CMS coverage for a novel device is a tough hurdle.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eLow. Competitors face the same long, complex process to gain similar broad coverage.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The company is clearly organized to exploit this, as evidenced by the high percentage of revenue derived from this source.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eOrders and insurance authorizations were received for \u003cstrong\u003e213\u003c\/strong\u003e MyoPro units in Q1 2025, up \u003cstrong\u003e18%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA record \u003cstrong\u003e700\u003c\/strong\u003e new candidates were added to the patient pipeline in Q1 2025, up \u003cstrong\u003e42%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e300\u003c\/strong\u003e Certified Prosthetists Orthotists have completed initial MyoPro® training as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. This established payer relationship is a significant moat against new entrants who lack this critical access.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: Orthotics and Prosthetics (O\u0026amp;P) Channel Penetration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOrthotics and Prosthetics (O\u0026amp;P) Channel Penetration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Creates a scalable, lower-cost distribution path, with O\u0026amp;P revenue hitting a record \u003cstrong\u003e$900k in Q3 2025\u003c\/strong\u003e, up \u003cstrong\u003e154%\u003c\/strong\u003e year-over-year. The O\u0026amp;P channel represented \u003cstrong\u003e9%\u003c\/strong\u003e of total Q3 2025 revenue of \u003cstrong\u003e$10.1 million\u003c\/strong\u003e. The overall patient pipeline stood at \u003cstrong\u003e1,669\u003c\/strong\u003e patients as of September 30, 2025, an increase of \u003cstrong\u003e32%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eO\u0026amp;P Channel (Q3 2025)\u003c\/th\u003e\n\u003cth\u003eTotal Company (Q3 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$900,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-Year Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e154%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Units Delivered\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e186\u003c\/strong\u003e (up \u003cstrong\u003e16%\u003c\/strong\u003e Y-o-Y)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Selling Price (ASP)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$54,300\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eRarity: Moderate. Many medical device firms use O\u0026amp;P, but Myomo, Inc.’s success in training over \u003cstrong\u003e300\u003c\/strong\u003e certified prosthetist orthotists ('CPO's') was completed as of March 31, 2025, showing focused execution. In Q3 2025, the company added \u003cstrong\u003e826\u003c\/strong\u003e new candidates to the pipeline, up \u003cstrong\u003e28%\u003c\/strong\u003e from Q3 2024.\u003c\/p\u003e\n\u003cp\u003eImitability: Moderate. Competitors can hire sales reps, but building this specific network of trained clinicians takes time and effort.\u003c\/p\u003e\n\u003cp\u003eOrganization: High. Management is actively pushing this channel, viewing it as a more scalable way to grow the pipeline. The company reiterated its full 2025 annual revenue guidance of \u003cstrong\u003e$40 million to $42 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedicare Part B patients represented \u003cstrong\u003e54%\u003c\/strong\u003e of Q3 2025 revenue.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 saw \u003cstrong\u003e229\u003c\/strong\u003e MyoPro orders, the strongest quarter of the year.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term investments as of September 30, 2025, were \u003cstrong\u003e$12.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCompetitive Advantage: Temporary. It’s a strong growth driver now, but sustained advantage requires continuous channel support and relationship building.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: MyoConnect Referral Platform\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A strategic initiative designed to generate recurring, high-quality patient referrals, aiming to lower the Cost Per Pipeline Add over time.\u003c\/p\u003e\n\u003cp\u003eThe platform's success is linked to efficiency improvements in customer acquisition, with management focused on a sequential reduction in cost per pipeline add through investment in MyoConnect and the O\u0026amp;P channel.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003cth\u003eQ1 2024\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Per Pipeline Add\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,618\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,597\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSequential reduction targeted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Patient Candidates Added (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e645\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e493\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e826\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patient Pipeline (End of Quarter)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,263\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,112\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,611\u003c\/strong\u003e (as of Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. A dedicated, formalized program focused on building a national network of referring therapists and physicians is not common in this niche.\u003c\/p\u003e\n\u003cp\u003eThe O\u0026amp;P channel expansion, which supports the referral network goal, saw revenue reach \u003cstrong\u003e$900,000\u003c\/strong\u003e in Q3 2025, representing a \u003cstrong\u003e154%\u003c\/strong\u003e year-over-year increase.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. It requires deep clinical engagement and relationship management, not just a marketing spend.\u003c\/p\u003e\n\u003cp\u003eThe O\u0026amp;P practitioner network expansion demonstrates this relationship focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e300\u003c\/strong\u003e Certified Prosthetist Orthotists (CPOs) had completed initial MyoPro training as of Q1 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e160\u003c\/strong\u003e CPOs were trained by the end of 2024 to establish MyoPro Centers of Excellence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. Early results are encouraging, but the company is still adjusting marketing to improve lead quality after early Q1 challenges.\u003c\/p\u003e\n\u003cp\u003eThe company has taken organizational steps to address efficiency:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eIn early 2025, advertising efficiency was temporarily impacted by Meta policy changes, leading to higher cost per pipeline add in January and February.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eLead generation improved in March 2025, with the cost per lead in April being roughly half of that in January and February.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eA new head of marketing was hired in Q3 2025 to optimize direct-to-consumer and B2B outreach.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$3.7 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. If it successfully creates a self-sustaining referral loop, it becomes a powerful, hard-to-replicate asset.\u003c\/p\u003e\n\u003cp\u003eThe goal is to rely less on advertising-driven revenues and generate growth through MyoConnect and the O\u0026amp;P channel in 2026.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: International Market Foothold (Germany Focus)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e International revenue reached a record of \u003cstrong\u003e$1.8 million\u003c\/strong\u003e in Q3 2025, representing \u003cstrong\u003e18%\u003c\/strong\u003e of total revenue and demonstrating a \u003cstrong\u003e63%\u003c\/strong\u003e year-over-year growth rate. This provides crucial revenue diversification away from the U.S. market. For context, Q1 2025 international revenue, primarily from Germany, was \u003cstrong\u003e$1.3 million\u003c\/strong\u003e, a \u003cstrong\u003e42%\u003c\/strong\u003e year-over-year increase.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Establishing a successful, consistent revenue stream in a major non-U.S. market like Germany is uncommon for firms of Myomo's scale. The Q3 2025 international revenue of \u003cstrong\u003e$1.8 million\u003c\/strong\u003e marks a record high.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The complexity and time required to navigate foreign regulatory approvals and establish distribution channels in the European Union present barriers to immediate imitation by rivals.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management explicitly targets international expansion as a key area for growth and diversification into 2026. The company delivered \u003cstrong\u003e186\u003c\/strong\u003e MyoPro revenue units in Q3 2025, with international performance being a driver. The full-year 2025 revenue guidance is reiterated at \u003cstrong\u003e$40 million to $42 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While the success in Germany proves international scalability, sustained advantage requires replicating this success across multiple foreign jurisdictions.\u003c\/p\u003e\n\n\u003cp\u003eThe following table details key revenue components from the Q3 2025 financial results:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue (Primarily Germany)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eO\u0026amp;P Channel Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$900,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e154%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Billing Channel Revenue\u003c\/td\u003e\n\u003ctd\u003eImplied (Calculated)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOperational metrics supporting pipeline and future organization include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 MyoPro Orders and Insurance Authorizations: \u003cstrong\u003e229\u003c\/strong\u003e units.\u003c\/li\u003e\n\u003cli\u003eNew candidates added to the patient pipeline in Q3 2025: \u003cstrong\u003e826\u003c\/strong\u003e, up \u003cstrong\u003e28%\u003c\/strong\u003e from Q3 2024.\u003c\/li\u003e\n\u003cli\u003eTotal patients in the pipeline as of Q3 2025: \u003cstrong\u003e1,669\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term investments as of September 30, 2025: \u003cstrong\u003e$12.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: Patient Pipeline Depth and Growth Rate\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A deep pipeline ensures future revenue visibility; the pipeline stood at \u003cstrong\u003e1,611\u003c\/strong\u003e candidates as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e (up \u003cstrong\u003e37%\u003c\/strong\u003e YoY). The company added \u003cstrong\u003e816\u003c\/strong\u003e medically-qualified patients in Q2 2025, representing a \u003cstrong\u003e49%\u003c\/strong\u003e year-over-year increase for that quarter. Medicare Part B patients represented \u003cstrong\u003e56%\u003c\/strong\u003e of Q2 2025 revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Adding a record \u003cstrong\u003e700\u003c\/strong\u003e new medically qualified candidates in Q1 2025 shows strong top-of-funnel capability. The company also expanded its contracting to cover \u003cstrong\u003e35 million\u003c\/strong\u003e lives with signed or pending agreements.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Generating high-quality leads is hard, as evidenced by the increase in acquisition cost. The Cost per direct billing pipeline add was \u003cstrong\u003e$2,300\u003c\/strong\u003e in Q1 2025 (up \u003cstrong\u003e31%\u003c\/strong\u003e YoY), surging to \u003cstrong\u003e$2,926\u003c\/strong\u003e in Q2 2025 (up \u003cstrong\u003e89%\u003c\/strong\u003e YoY). Competitors can increase ad spend, but the quality of leads from specific channels (e.g., Facebook) has proven variable.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. While volume growth was strong in Q1, the company noted explicit challenges with lead quality and conversion in Q2, showing organizational strain requiring strategic shifts. Management responded with decisive action, including shifting advertising focus from digital to television and reducing headcount by about \u003cstrong\u003e8%\u003c\/strong\u003e in July, expected to save $\\ge$\u003cstrong\u003e$2 million\u003c\/strong\u003e over the next 12 months.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Pipeline volume is a function of marketing spend and channel effectiveness, which can be matched or exceeded, as shown by the rising Cost per pipeline add. The company is attempting to build a more sustainable advantage through the MyoConnect program, aiming to engage more therapists and physicians for recurrent, higher-quality referrals.\u003c\/p\u003e\n\n\u003cp\u003eKey Pipeline and Cost Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Pipeline Depth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,611\u003c\/strong\u003e candidates\u003c\/td\u003e\n\u003ctd\u003eAs of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e37%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eAs of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e vs. June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Candidates Added\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e816\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Candidate YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e49%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs. Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecord New Candidates Added\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e700\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Per Pipeline Add\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,926\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Per Pipeline Add YoY Change\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e89%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs. Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOrganizational Adjustments and Channel Expansion:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company completed initial training for more than \u003cstrong\u003e300\u003c\/strong\u003e Certified Prosthetist Orthotists (CPO's) as of \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e, up from \u003cstrong\u003e160\u003c\/strong\u003e at the start of the year.\u003c\/li\u003e\n\u003cli\u003eThe number of O\u0026amp;P orders doubled from Q1 to Q2 of 2025.\u003c\/li\u003e\n\u003cli\u003eAdvertising expense in Q2 2025 was \u003cstrong\u003e$2.2 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e162%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eThe company has trained over \u003cstrong\u003e1,500\u003c\/strong\u003e occupational therapists on the MyoPro across the country.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: Product Iteration Velocity (MARK 2 and MyoPro 2x)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Continuous product upgrades maintain technological relevance and ASP support.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eLaunch Date\u003c\/th\u003e\n\u003cth\u003eKey Improvement Area\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMARK 2 (Clinical Unit)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e3D printed shells, 'One Size Fits All' design\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyoPro 2x\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMinimize donning time, improve sensor contact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eASP in Q3 2024 was approximately \u003cstrong\u003e$57,200\u003c\/strong\u003e, up \u003cstrong\u003e35%\u003c\/strong\u003e year-over-year, or approximately \u003cstrong\u003e$52,700\u003c\/strong\u003e excluding certain payments, up \u003cstrong\u003e23%\u003c\/strong\u003e. Revenue recognized on \u003cstrong\u003e161\u003c\/strong\u003e MyoPro units in Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Commitment to rapid, incremental improvement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can copy features, but the internal engineering culture that drives this pace is harder to duplicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. R\u0026amp;D investment supports this capability.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating expenses for Q3 2024 were \u003cstrong\u003e$7.9 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e43%\u003c\/strong\u003e compared with Q3 2023.\u003c\/li\u003e\n\u003cli\u003eThe increase in Q3 2024 operating expenses was driven primarily by higher payroll expense due to additional headcount to support the Company's \u003cstrong\u003eengineering efforts\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company holds \u003cstrong\u003e35 Patents\u003c\/strong\u003e in U.S. and International markets valid through \u003cstrong\u003e2042\u003c\/strong\u003e, with additional patents pending.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It keeps them ahead today, but sustained advantage requires patents and constant reinvestment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: Direct-to-Patient\/Provider Sales Expertise\u003c\/h2\u003e\n\n\u003cp\u003eThe analysis below is based on Myomo, Inc.'s financial and operating highlights for the first quarter ended March 31, 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eQ1 2025 Data Point\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e162%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Units Recognized\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e182\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e100%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Selling Price (ASP)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$54,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e31%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part B Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e59%\u003c\/strong\u003e of Q1 2025 revenue\u003c\/td\u003e\n\u003ctd\u003eReflects direct payer\/patient channel reliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Patient Pipeline Adds\u003c\/td\u003e\n\u003ctd\u003eRecord \u003cstrong\u003e700\u003c\/strong\u003e candidates\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e42%\u003c\/strong\u003e from Q1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patient Pipeline\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,482\u003c\/strong\u003e candidates (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e33%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Per Pipeline Add\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e31%\u003c\/strong\u003e from Q1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eDirect-to-Patient\/Provider Sales Expertise\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to manage complex sales cycles directly with patients and specialized providers, evidenced by Medicare Part B patients representing \u003cstrong\u003e59%\u003c\/strong\u003e of first quarter 2025 revenue. The company recognized revenue on \u003cstrong\u003e182\u003c\/strong\u003e MyoPro units in Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Selling high-cost, complex medical robotics requires a specialized, empathetic sales force that is difficult to hire quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This is tacit knowledge built over years of dealing with patient needs and insurance complexities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company has built its foundation on this direct model, even as it diversifies. The organization supports this through clinical training expansion.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial training of more than \u003cstrong\u003e300\u003c\/strong\u003e Certified Prosthetist Orthotists ('CPO's') was completed as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company added a record \u003cstrong\u003e700\u003c\/strong\u003e new medically-qualified candidates to the patient pipeline in Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The institutional knowledge embedded in the sales and clinical teams is a core, non-codified asset.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyomo, Inc. (MYO) - VRIO Analysis: Balance Sheet Strength and Capital Access\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProvides the necessary runway to fund operations and R\u0026amp;D; cash was $12.6 million as of September 30, 2025, bolstered by a $17.5 million committed term loan, with $12.5 million funded on November 4, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (as of Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003ePost-Quarter Event\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.55 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12.5 million\u003c\/strong\u003e funded from new loan on November 4, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevolving Credit Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNew loan provides up to \u003cstrong\u003e$17.5 million\u003c\/strong\u003e committed capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerm Loan Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOperating Cash Outflow YTD: \u003cstrong\u003e$13.37 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e38,435,524\u003c\/strong\u003e (as of Nov 3, 2025)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Net Loss: \u003cstrong\u003e$3.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eLow. Many public companies have access to capital markets, though securing a term loan adds flexibility. The company had $1.0 million outstanding on its revolving credit line and $3.0 million under its term loan facility as of September 30, 2025.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow. Access to capital is generally market-dependent and not a unique operational skill. The company reported year-to-date revenue of $29.57 million versus $20.48 million the prior year for the same period.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eYear-to-date operating loss was \u003cstrong\u003e$11.6 million\u003c\/strong\u003e for the nine months ended September 30, 2025, compared with an operating loss of \u003cstrong\u003e$6.0 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin was \u003cstrong\u003e63.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected full-year 2025 revenue guidance is within the range of \u003cstrong\u003e$40 million\u003c\/strong\u003e to \u003cstrong\u003e$42 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh. Management successfully secured financing to fund operations through the next 12 months, showing financial planning. The company expects current cash and expected cash flows to be sufficient to fund operations for at least the next twelve months.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone. This is a necessary condition for operation, not a source of advantage over peers with similar access.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516213223573,"sku":"myo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/myo-vrio-analysis.png?v=1740197191","url":"https:\/\/dcf-model.com\/pt\/products\/myo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}